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Measuring coagulation in  
burns: an evidence-based  
systematic review
Nicholas J. Marsden1,2, Martin Van2, Samera Dean2, 
Ernest A. Azzopardi2,3, Sarah Hemington-Gorse2, 
Phillip A. Evans1,3 and Iain S. Whitaker2,3
Abstract
Introduction: Dynamic monitoring of coagulation is important to predict both haemorrhagic and thrombotic 
complications and to guide blood product administration. Reducing blood loss and tailoring blood product 
administration may improve patient outcome and reduce mortality associated with transfusion. The current 
literature lacks a systematic, critical appraisal of current best evidence on which clinical decisions may be 
based.
Objectives: Establishing the role of different coagulation markers in burn patients, diagnosing coagulopathy, 
tailoring blood product administration and indicating prognosis.
Methods: Literature during 2004–2017 from the Cochrane Library, PubMed, Scopus, Medline and Embase 
was reviewed. Eligibility criteria included randomised controlled trials, systematic reviews, multi-/single-centre 
study and meta-analyses. Keywords searched were ‘burns’, ‘blood coagulation disorders’, ‘rotem’, ‘blood 
coagulation’ and ‘thromboelastography’. The PRISMA flow system was used for stratification and the CASP 
framework for appraisal of the studies retrieved.
Results: In total, 13 articles were included after inclusion/exclusion criteria had been applied to the initial 
79 studies retrieved. Hypercoagulation increases in proportion to the severity of thermal injury. Whole 
blood testing, using thrombelastography (TEG) and rotation thromboelastometry (ROTEM), was superior 
to standard plasma based tests, including prothrombin time (PT) and activated partial thromboplastin time 
(APTT) at detecting burn-related coagulopathies.
Conclusions: Routine laboratory markers such as PT/APTT are poor indicators of coagulation status in 
burns patients. Viscoelastic tests, such as TEG and ROTEM, are efficient, fast and have a potential use in the 
management of burn patients; however, strong evidence is lacking. This review highlights the need for more 
randomised controlled trials, to guide future practice.
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Lay Summary
Introduction: It is important to measure how easily or how difficult it is for blood to clot in patients who 
have sustained severe burn injuries. By doing this, we can predict bleeding and blood-clotting risks and it 
can help us determine when blood transfusions are needed. The medical literature does not currently have 
any articles which systematically summarise the best evidence regarding this topic.
Methods: Databases containing medical research articles were searched in a systematic way and each article 
was scrutinised for its quality and how reliable the conclusions are based on how the study was performed.
Results: Seventy-nine scientific articles were identified and narrowed down to 13 relevant ones. Patients 
with larger burn injuries are more likely to suffer abnormalities in their blood which leads to blood clotting 
more easily than normal. Blood tests called thrombelastography (TEG) and rotation thromboelastometry 
(ROTEM) seemed to be better than standard blood tests called prothrombin time (PT) and activated 
partial thromboplastin time (APTT) at detecting clotting disorders in burn patients.
Conclusions: Standard blood clotting tests such as PT and APTT are not good at detecting blood-clotting 
abnormalities in burns patients. Other tests, TEG and ROTEM, are an efficient and fast way of monitoring 
blood clotting in burns patients. These tests have a potential use in the treatment of burns patients, but 
strong evidence to support this statement is lacking. This study highlights the need for more evidence, 
especially bigger and better research studies to guide future recommendations.
Introduction
Thermal injury involves a complex interplay 
between early activation of uncontrolled coagula-
tion and fibrinolysis, coupled with an increase in 
various inflammatory mediators.1–3 Bleeding 
remains a major challenge during early exci-
sional surgery and is a predictor of mortality.4,5 A 
study investigating burn injuries > 40% total 
body surface area (TBSA) found that the median 
red blood cell (RBC) and plasma transfusion 
required was 19 units and 28.5 units, respectively, 
during an admission.6 Coagulopathy has been 
repeatedly identified as a risk factor for increased 
morbidity and mortality in the early post-burn 
period as well as in later clinical course.7,8 
Although the underlying pathophysiology 
behind this coagulopathy is not completely 
understood, the body of knowledge in this area 
has increased in recent years. Patients may 
require a significant amount of blood products 
which worsen the patient’s prognosis due to 
defects in the ability of fibrinogen to form firm 
clots, increased chance of infectious complica-
tions, organ failure and respiratory distress.9 A 
combination of reducing blood loss and tailoring 
blood product administration could improve 
patient outcome and reduce mortality. Evidence 
in other specialties such as trauma and cardiac 
surgery demonstrates blood transfusions in 
bleeding patients can be reduced with rapid and 
targeted correction of coagulopathy;10 whether 
this applies to burn patients is unknown.
Traditionally, plasma-based routine coagula-
tion tests, including activated partial thrombo-
plastin time (APTT) and prothrombin time 
(PT), are used to monitor coagulopathy. These 
tests are adequate predictors of mortality in 
trauma patients; however, as APTT and PT only 
reflect the small amount of thrombin formed 
during the acute phase of coagulation, they are 
of limited use in the management of burns 
patients. Following burn injury, the patient’s 
coagulation status may change considerably as a 
response to the systemic inflammatory response 
over the first week, and as a result of interven-
tions such as haemodilution and during fluid 
resuscitation and excisional surgery.8,11 An addi-
tional confounding variable is that APTT and PT 
are performed under non-physiological condi-
tions and the delay in processing often means the 
patient’s condition has changed significantly 
before the results become available.
These limitations have led to increased inter-
est in point of care (POC) tests that analyse whole 
blood to identify coagulopathies, such as thromb-
elastography (TEG) and rotational thromboelas-
tometry (ROTEM). These tests have been used for 
over 20 years to guide blood transfusion in liver 
transplantation and cardiac surgery.12–14 In TEG 
and ROTEM analysis, a small amount of whole 
blood (1 mL or less) is added to a cup with a cen-
tral pin. The rotating motion of the cup in the 
case of TEG, or the pin in the ROTEM system, 
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detects the increase in tension as the clot forms 
and gives a graphic representation of the viscoelas-
tic changes at all stages of the developing and 
resolving clot. A full discussion of these tests is 
beyond the scope of this review and is described in 
detail elsewhere.13,15 TEG and ROTEM allow both 
the severity and prognosis to be predicted, the 
treatment to be tailored and the effect to be evalu-
ated. They are also easy to use by non-trained per-
sonnel and the results are available within 10–20 
min, which is much quicker than APTT or PT, 
leading to their use as POC bedside tests.15,16 The 
real-time monitoring allows for rapid clinical 
decision-making in the emergency settings of 
haemorrhage, preventing delays and enabling 
early tailored blood product administration. In 
contrast to its many advantages, limitations of 
TEG and ROTEM include the frequent quality 
control and calibration of the equipment required 
and the inter-rater variability which has shown 
variable precision between operators.17 The role 
of TEG or ROTEM in managing burn injury is 
not well characterised, although it has the poten-
tial to be of significant use and may be superior to 
traditional coagulation tests because of its dynamic 
and quick results in the acute burn injury setting.
Objectives
This study establishes the role of different coagu-
lation markers in burn patients and assess their 
potential role in diagnosing coagulopathy, tailor-
ing blood product administration and indicating 
prognosis.
Methods
Aim construct
The terms of reference in Patient Intervention 
Comparator and Outcome (PICO) format are 
reported in the supplementary data (S1), con-
forming to pre-validated criteria.18
Literature search
A comprehensive literature search was con-
ducted between March and April 2017 in line 
with the Cochrane Handbook for Systematic Reviews 
of Interventions.19 The Cochrane Library, PubMed, 
Scopus, Medline (OVID) and Embase (Ovid) 
databases were searched for articles with regards 
to burns, coagulation disorders and TEG and 
ROTEM. Primary studies of randomised con-
trolled trials (RCTs), systematic reviews, multi-/
single-centre studies, meta-analyses, case series 
in English and human participants over the last 
13 years were included with the following 
Boolean and Medical Subject Headings (MeSH) 
‘Burns’[MeSH] ((‘Blood coagulation disorders’ 
[MeSH] OR rotem[TiAb]) OR ‘Blood coagulation’ 
[MeSH]) OR ‘thromboelastography’[MeSH] 
(see Figure 1). Other criteria for inclusion were 
studies that included TEG, ROTEM, coagulation 
tests, and anticoagulant factors or disseminated 
intravascular coagulation (DIC) in burn patients. 
Case studies and articles only considering non-
burn trauma were excluded. Finally, all results 
were independently screened and assessed by 
two researchers to identify any relevant studies 
for inclusion and the final set was agreed upon 
by serial discussion/assessment rounds for any 
discrepancy in selection. Cohen’s kappa coeffi-
cient was calculated at each stage of title, abstract 
and full text review to ascertain inter-rater varia-
bility between the two reviewers.
Reporting of the systematic review and 
evidence-based process
PRISMA guidelines were applied to report the 
systematic review and evidence-based process. 
The retrieval process reported only two RCTs due 
to the novel nature of the topic, requiring these 
guidelines to be adapted. Systematic review of 
studies other than RCTs is not new,20 and so case 
series, reviews (best balance of sensitivity and 
specificity) and cohort studies at multi/single 
centres were also included. To ensure compara-
bility, rigorous critical appraisal was applied to 
determine the quality of the studies retrieved 
and ensure inclusion of comparable, valid and 
relevant evidence.21 All literature was appraised 
using the approved Critical Appraisal Skills 
Programme (CASP) framework, which assesses 
articles for validity, results, uncertainty and appli-
cability to the considered population.22
A table (Table 1) was formulated and used to 
extract the data from each study, including the 
type of study, outcome of interest, participant 
information, results summary, conclusion and 
level of evidence. The strengths and limitations 
of each study were discussed therein.
Types of studies
All meta-analyses and RCTs were included. In 
anticipation of insufficient numbers of trials (n 
< 3) due to the novel nature of this topic, case 
series, reviews (best balance of sensitivity and 
specificity) and cohort studies at multi/single 
centres were also included.
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Outcome data
Outcomes of interest were: the potential role of 
anticoagulant factors; coagulation markers in 
burn injury and any association with DIC; coagu-
lation tests that had the potential to diagnose 
burn-associated coagulopathy, tailor blood prod-
uct administration and provide an indication of 
prognosis.
Results
Search results
A total of 79 publications relating to burns and 
coagulation, with specific reference to the latter, 
were identified. Irrelevant and duplicate studies 
and those not fulfilling the inclusion and exclusion 
criteria were identified using manual checking and 
eliminated through serial assessment rounds by 
establishing inter-rater agreement (Figure 1). 
Thirteen full-text publications contributed to this 
systematic review (Table 1). Agreement between 
reviewers was high with Cohen’s kappa coefficient 
calculated as 0.74, 0.89 and 1 for the title, abstract 
and full-text review stages, respectively.
Participants and settings
Population. Our review included 3821 patients 
across 11 studies. The critical appraisal process 
reported two level 5,23,24 one level 4 (five 
patients),25 five level 2b (205 patients),3,14,26–28 
Figure 1. Flow chart of literature retrieval.
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ia
 in
 te
rm
s 
of
 p
at
ie
nt
 
ch
ar
ac
te
ris
tic
s 
an
d 
cl
as
si
fy
in
g 
bl
ee
di
ng
.
St
an
da
rd
is
ed
 te
st
 (R
O
TE
M
).
Bl
oo
d 
lo
ss
 d
ur
in
g 
an
d 
af
te
r 
su
rg
er
y 
no
t m
ea
su
re
d 
to
 e
lim
in
at
e 
po
ss
ib
ili
ty
 fo
r d
iff
er
en
ce
 in
 b
lo
od
 
pr
od
uc
ts
 re
ce
iv
ed
.
Sh
or
t s
tu
dy
 p
er
io
d 
(2
4 
h)
.
Sm
al
l s
am
pl
e 
si
ze
.
U
se
 o
f c
oa
gu
la
tio
n 
te
st
s 
in
 c
on
ju
nc
tio
n 
w
ith
 a
 
pe
rio
pe
ra
tiv
e 
tr
ea
tm
en
t 
al
go
rit
hm
 in
 a
cu
te
 
bl
ee
di
ng
 s
itu
at
io
ns
 c
an
 
al
lo
w
 fo
r t
ai
lo
re
d 
th
er
ap
y 
in
 te
rm
s 
of
 re
du
ce
d 
bl
oo
d 
pr
od
uc
ts
 a
nd
 a
vo
id
an
ce
 o
f 
un
ne
ce
ss
ar
y 
pr
oc
oa
gu
la
nt
 
tr
ea
tm
en
t.
1b
Ba
rr
et
 e
t a
l.,
 
20
05
26
M
ul
tic
en
tr
e,
 
re
tr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
dy
Re
vi
ew
ed
 s
ig
ns
, s
ym
pt
om
s 
an
d 
co
ag
ul
at
io
n 
st
at
us
 to
 
el
uc
id
at
e 
in
ci
de
nc
e 
an
d 
cl
in
ic
al
 
im
pl
ic
at
io
ns
 o
f a
ll 
pa
tie
nt
s 
di
ag
no
se
d 
w
ith
 D
IC
.
n 
=
 3
33
1
A
du
lts
, n
 =
 2
40
8;
 
ch
ild
re
n,
 n
 =
 9
23
;
62
.5
%
 m
al
e,
37
.5
%
 fe
m
al
e;
13
.6
%
 o
ve
r 2
0%
 T
BS
A
.
O
nl
y 
ad
ul
t p
at
ie
nt
s 
af
fe
ct
ed
 b
y 
D
IC
 a
nd
 h
ad
 a
lte
re
d 
co
ag
ul
at
io
n.
 
N
o 
ag
e/
ge
nd
er
 p
re
fe
re
nc
e.
 3
/3
33
1 
pr
es
en
te
d 
w
ith
 c
lin
ic
al
 s
ig
ns
 o
f 
D
IC
, c
on
fir
m
ed
 b
y 
th
e 
la
b.
2 
pa
tie
nt
s 
ha
d 
D
IC
 a
ft
er
 b
ur
n 
ex
ci
si
on
.
M
or
ta
lit
y 
w
as
 1
.7
7%
 b
ut
 n
ot
 d
ue
 to
 
a 
di
re
ct
 c
on
se
qu
en
ce
 o
f D
IC
.
La
rg
e 
sa
m
pl
e 
si
ze
.
Pa
tie
nt
s 
fr
om
 th
e 
U
K 
ce
nt
re
 w
er
e 
on
ly
 in
cl
ud
ed
 if
 tr
ea
te
d 
by
 th
e 
se
ni
or
 a
ut
ho
r, 
w
hi
ch
 in
tr
od
uc
es
 
se
le
ct
io
n 
bi
as
.
Lo
ng
 s
tu
dy
 p
er
io
d,
 b
ut
 n
ot
 d
at
es
.
Re
al
 in
ci
de
nc
e 
of
 D
IC
 w
ou
ld
 
ne
ed
 to
 b
e 
de
te
rm
in
ed
 u
si
ng
 a
 
pr
os
pe
ct
iv
e 
m
ul
tic
en
tr
e 
st
ud
y.
D
IC
 is
 ra
re
 a
nd
 p
re
se
nt
s 
m
ai
nl
y 
in
 s
ev
er
e 
bu
rn
s.
Ro
ut
in
e 
sc
re
en
in
g 
fo
r D
IC
 
is
 n
ot
 n
ee
de
d 
bu
t i
n 
th
e 
pr
es
en
ce
 o
f a
lte
re
d 
an
d 
un
ex
pl
ai
na
bl
e 
co
ag
ul
at
io
n 
an
d 
pl
at
el
et
 le
ve
ls
, D
IC
 
sh
ou
ld
 b
e 
in
ve
st
ig
at
ed
.
3b
Pa
rk
 e
t a
l.,
 
20
08
23
Si
ng
le
-c
en
tr
e,
 
pr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
dy
M
ea
su
re
m
en
t o
f c
oa
gu
la
tio
n 
an
d 
in
fla
m
m
at
or
y 
pa
ra
m
et
er
s 
at
 ti
m
e 
of
 h
os
pi
ta
l a
dm
is
si
on
 
to
 p
re
di
ct
 in
-h
os
pi
ta
l m
or
ta
lit
y.
n 
=
 5
8
n 
=
 3
3 
tr
au
m
a 
pa
tie
nt
s 
(7
8%
 m
en
);
n 
=
 2
5 
bu
rn
ed
 p
at
ie
nt
s 
(7
2%
 m
en
);
n 
=
 2
0 
he
al
th
y 
co
nt
ro
ls
 
(5
5%
 m
en
).
Si
gn
ifi
ca
nt
 d
iff
er
en
ce
 b
et
w
ee
n 
th
e 
pr
ob
ab
ili
ty
 o
f m
or
ta
lit
y 
us
in
g 
co
ag
ul
at
io
n 
an
d 
in
fla
m
m
at
or
y 
pa
ra
m
et
er
s 
vs
. a
ct
ua
l m
or
ta
lit
y 
P 
<
 0
.0
01
.
Fi
rs
t s
co
rin
g 
sy
st
em
 th
at
 u
se
s 
co
ag
ul
at
io
n 
an
d 
in
fla
m
m
at
or
y 
pa
ra
m
et
er
s.
Pa
rt
ic
ip
an
t i
nc
lu
si
on
/e
xc
lu
si
on
 
cr
ite
ria
 c
le
ar
ly
 s
ta
te
d.
N
o 
ot
he
r c
o-
m
or
bi
di
tie
s 
ot
he
r t
ha
n 
ag
e 
ta
ke
n 
in
to
 a
cc
ou
nt
; t
he
re
fo
re
 
po
te
nt
ia
lly
 in
ac
cu
ra
te
.
Co
m
bi
ne
d 
tr
au
m
a 
an
d 
bu
rn
s 
in
ju
rie
s 
w
er
e 
no
t c
on
si
de
re
d.
Sm
al
l s
am
pl
e 
si
ze
.
Co
nt
ro
ls
 m
uc
h 
yo
un
ge
r a
nd
 m
or
e 
m
en
 in
 th
e 
st
ud
y.
Co
ag
ul
at
io
n 
an
d 
in
fla
m
m
at
or
y 
pa
ra
m
et
er
s 
ca
n 
be
 u
se
d 
to
 p
re
di
ct
 th
e 
pr
ob
ab
ili
ty
 o
f m
or
ta
lit
y.
A
pp
lic
ab
le
 to
 tr
au
m
at
ic
 
an
d 
bu
rn
 in
ju
rie
s.
2b
Sc
ha
de
n 
et
 a
l.,
 2
01
22
4
Si
ng
le
-c
en
tr
e,
 
pr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
dy
Fi
br
in
og
en
 le
ve
ls
 in
 s
ev
er
e 
bu
rn
s 
pa
tie
nt
s 
m
ea
su
re
d 
us
in
g 
RO
TE
M
n 
=
 2
0
A
ge
 5
3 
±
 2
2 
ye
ar
s,
m
al
e/
fe
m
al
e 
14
/6
,
%
 T
BS
A
 4
2.
55
 ±
 2
1.
81
N
o 
th
ro
m
bo
tic
/b
le
ed
in
g 
ev
en
ts
 
w
ith
in
 4
8 
h 
of
 a
dm
is
si
on
.
Fi
br
in
og
en
 in
iti
al
ly
 n
or
m
al
 b
ut
 
in
cr
ea
se
d 
24
–4
8 
h.
A
ft
er
 4
8 
h,
 6
5%
 o
f p
at
ie
nt
s 
ha
d 
si
gn
ifi
ca
nt
 in
cr
ea
se
 in
 fi
br
in
og
en
 
(P
 =
 0
.0
02
).
Sm
al
l p
op
ul
at
io
n 
an
d 
sa
m
pl
e 
si
ze
. 
A
ge
 b
ia
s 
(e
xc
lu
si
on
 o
f <
 1
8 
ye
ar
s)
.
Re
gu
la
r b
lo
od
 s
am
pl
es
 ta
ke
n 
bu
t v
ar
ie
d 
tr
ea
tm
en
t c
ou
rs
es
 n
ot
 
ac
co
un
te
d 
fo
r.
M
ea
su
re
m
en
ts
 o
nl
y 
ta
ke
n 
in
 th
e 
fir
st
 4
8 
h;
 th
er
ef
or
e 
m
ay
 h
av
e 
m
is
se
d 
la
te
r c
ha
ng
es
 in
 fi
br
in
og
en
.
Te
st
s 
m
ea
su
rin
g 
fib
rin
og
en
 
co
ul
d 
he
lp
 ta
ilo
r 
th
er
ap
eu
tic
 m
ea
su
re
s 
fo
r 
bu
rn
s 
pa
tie
nt
s.
Th
is
 w
ou
ld
 s
av
e 
co
st
 a
nd
 
un
ne
ce
ss
ar
y 
us
e 
of
 fr
es
h 
fr
oz
en
 p
la
sm
a.
2b
Ta
bl
e 
1.
 (C
on
tin
ue
d)
Marsden et al. 7
A
ut
ho
r, 
da
te
St
ud
y 
ty
pe
O
ut
co
m
e
Pa
ti
en
ts
 (n
)/
 d
et
ai
ls
Re
su
lt
s
Co
m
m
en
ts
Co
nc
lu
si
on
Le
ve
l o
f 
ev
id
en
ce
Ki
ng
 e
t a
l.,
 
20
10
22
Si
ng
le
-c
en
tr
e,
 
pr
os
pe
ct
iv
e 
ca
se
 
se
rie
s
Te
st
 u
se
fu
l m
ar
ke
rs
 fo
r 
hy
pe
rc
oa
gu
la
bl
e 
st
at
e 
in
 
ar
te
ria
l b
lo
od
 o
f b
ur
n 
pa
tie
nt
s 
at
 d
ay
s 
1,
 2
, 3
, 5
 a
nd
 7
 w
ith
 P
T,
 
A
PT
T,
 T
EG
, D
d,
 h
ae
m
at
oc
rit
, 
pl
at
el
et
s,
 A
T,
 F
VI
II,
 P
C,
 P
S.
n 
=
 5
 (4
 m
al
e;
 1
 fe
m
al
e)
n 
=
 2
 w
ith
 3
%
 T
BS
A
, n
 
=
 1
 w
ith
 6
%
 T
BS
A
, n
 =
 
1 
w
ith
 2
3%
 T
BS
A
, n
 =
 1
 
w
ith
 4
5%
 T
BS
A
.
A
ge
 ra
ng
e 
23
–4
7 
ye
ar
s,
 
m
ea
n 
ag
e 
32
 y
ea
rs
.
H
ae
m
at
oc
rit
 ra
is
ed
 in
 2
3%
 a
nd
 
45
%
 T
BS
A
 b
ur
n 
pa
tie
nt
s 
N
o 
pl
at
el
et
 a
bn
or
m
al
iti
es
. A
PT
T 
lo
w
es
t i
n 
45
%
 b
ur
n 
pa
tie
nt
.
PT
 a
nd
 A
PT
T 
no
rm
al
 in
 3
%
, 6
%
 a
nd
 
23
%
 T
BS
A
s.
FV
III
 n
or
m
al
 fo
r 3
%
, i
nc
re
as
ed
 
in
 6
%
 a
nd
 2
3%
. 4
5%
 o
f p
at
ie
nt
s 
sh
ow
ed
 in
cr
ea
se
 fo
r 2
 d
ay
s 
th
en
 
de
cr
ea
se
 u
nt
il 
da
y 
7.
 D
d 
in
cr
ea
se
d 
in
 3
%
, 2
3%
 a
nd
 4
5%
 b
ut
 in
cr
ea
se
d 
th
en
 d
ec
re
as
ed
 b
y 
da
y 
3 
in
 6
%
 
pa
tie
nt
. P
C,
 P
S 
an
d 
A
T 
re
m
ai
ne
d 
no
rm
al
 fo
r 3
%
, 6
%
 a
nd
 2
3%
 b
ur
ns
 
bu
t i
nc
re
as
ed
 s
ig
ni
fic
an
tly
 in
 4
5%
 
pa
tie
nt
 (n
o 
P 
va
lu
e)
.
TE
G
 n
or
m
al
 fo
r 3
 a
nd
 6
%
 b
ur
ns
. 
In
cr
ea
si
ng
 in
 2
3%
 a
nd
 d
ec
re
as
in
g 
in
 4
5%
 b
ur
ns
.
Ve
ry
 s
m
al
l s
am
pl
e 
si
ze
. P
os
si
bl
e 
se
le
ct
io
n 
bi
as
, w
hi
ch
 li
m
its
 
ac
ce
pt
an
ce
 o
f c
au
sa
lit
y.
Lo
w
er
 o
n 
th
e 
hi
er
ar
ch
y 
of
 e
vi
de
nc
e.
U
nk
no
w
n 
if 
co
ns
ec
ut
iv
e 
or
 n
on
-
co
ns
ec
ut
iv
e 
ca
se
 s
er
ie
s.
G
en
de
r b
ia
s.
Co
-m
or
bi
di
tie
s,
 in
cl
ud
in
g 
H
IV
 a
nd
 
hy
pe
rt
en
si
on
, m
en
tio
ne
d 
bu
t n
ot
 
st
at
ed
 in
 w
hi
ch
 p
at
ie
nt
s;
 th
er
ef
or
e 
co
ul
d 
ha
ve
 c
on
fo
un
de
d 
th
e 
re
su
lts
.
Re
su
lts
 fo
r 3
%
 a
nd
 6
%
 T
BS
A
 
pa
tie
nt
s 
st
op
pe
d 
at
 d
ay
s 
2 
an
d 
3,
 
re
sp
ec
tiv
el
y;
 n
o 
re
as
on
 g
iv
en
.
Th
er
m
al
 in
ju
ry
 c
re
at
es
 a
 
hy
pe
rc
oa
gu
la
bl
e 
st
at
e 
pr
op
or
tio
na
l t
o 
th
e 
TB
SA
 
bu
rn
ed
.
Th
is
 is
 u
nd
et
ec
ta
bl
e 
w
ith
 
PT
 a
nd
 A
PT
T.
4
G
la
s 
et
 a
l.,
 
20
16
20
Li
te
ra
tu
re
 
re
vi
ew
D
es
cr
ib
in
g 
ep
id
em
io
lo
gy
 
an
d 
co
ag
ul
op
at
hy
 o
f p
at
ie
nt
s 
w
ith
 s
ev
er
e 
bu
rn
s 
an
d 
its
 
m
an
ag
em
en
t t
he
re
of
.
92
 jo
ur
na
l a
rt
ic
le
s 
re
fe
re
nc
ed
.
A
rt
ic
le
s 
pu
bl
is
he
d 
be
tw
ee
n 
19
73
 a
nd
 2
01
5.
N
o 
cl
ea
r c
on
se
ns
us
 o
n 
de
fin
iti
on
 
of
 c
oa
gu
lo
pa
th
y 
or
 d
ia
gn
os
tic
 
cr
ite
ria
. P
ro
co
ag
ul
an
t c
ha
ng
es
 
du
rin
g 
se
ve
re
 b
ur
ns
 in
cl
ud
e 
in
cr
ea
se
d 
TA
T,
 a
ct
iv
at
ed
 F
VI
Ia
 
an
d 
de
cr
ea
se
d 
le
ve
ls
 o
f A
T,
 P
C 
an
d 
PS
. V
TE
 in
ci
de
nc
e 
in
 b
ur
n 
pa
tie
nt
s 
in
 th
e 
ra
ng
e 
of
 0
.3
–2
3%
. 
A
dm
in
is
tr
at
io
n 
of
 A
T,
 A
PC
, l
oc
al
 
pu
lm
on
ar
y 
an
tic
oa
gu
la
nt
s 
an
d 
re
co
m
bi
na
nt
 F
VI
Ia
 in
 m
an
ag
em
en
t 
of
 c
oa
gu
lo
pa
th
y 
in
 b
ur
ns
 p
at
ie
nt
s 
ar
e 
m
ai
nl
y 
fr
om
 c
as
e 
re
po
rt
s 
or
 
sm
al
l s
tu
di
es
.
D
oe
s 
no
t s
ta
te
 th
e 
da
ta
ba
se
s 
an
d 
ke
yw
or
ds
 u
se
d 
to
 c
on
du
ct
 th
e 
re
vi
ew
. N
ot
 s
ys
te
m
at
ic
.
Fu
rt
he
r p
ro
sp
ec
tiv
e 
RC
Ts
 a
re
 n
ee
de
d 
to
 
gu
id
e 
m
an
ag
em
en
t o
f 
se
ve
re
 b
ur
n 
pa
tie
nt
s 
w
ith
 c
oa
gu
lo
pa
th
y 
as
 
th
is
 e
vi
de
nc
e 
is
 c
ur
re
nt
ly
 
la
ck
in
g.
5
Sh
er
re
n 
et
 a
l.,
 
20
13
28
Si
ng
le
-c
en
tr
e,
 
re
tr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
dy
Id
en
tif
yi
ng
 b
ur
n 
pa
tie
nt
s 
on
 
ad
m
is
si
on
 w
ho
 h
ad
 A
BI
C 
an
d 
its
 a
ss
oc
ia
te
d 
m
or
ta
lit
y.
M
ea
su
re
 P
T,
 A
PT
T 
an
d 
28
-d
ay
 
m
or
ta
lit
y.
n 
=
 1
17
 (6
4.
1%
 m
al
e)
TB
SA
 >
 3
0%
; m
ea
n 
po
pu
la
tio
n 
ag
e 
34
.8
 
ye
ar
s.
Pa
tie
nt
s 
w
ith
 A
BI
C 
ha
d 
a 
si
gn
ifi
ca
nt
ly
 in
cr
ea
se
d 
28
-d
ay
 
m
or
ta
lit
y 
ra
te
 3
9.
1%
 v
s.
 8
.5
%
 
in
 p
at
ie
nt
 g
ro
up
 w
ith
 n
or
m
al
 
co
ag
ul
at
io
n 
(P
 =
 0
.0
00
1)
.
In
cr
ea
se
d 
TB
SA
 o
f b
ur
n,
 in
ha
la
tio
n 
in
ju
ry
, i
nc
id
en
ce
 o
f f
ul
l t
hi
ck
ne
ss
 
bu
rn
 a
nd
 A
BS
I w
as
 p
re
di
ct
iv
e 
of
 
co
ag
ul
op
at
hy
.
Vu
ln
er
ab
le
 to
 b
ia
s 
du
e 
to
 2
8 
pa
tie
nt
s 
ex
cl
ud
ed
 fr
om
 a
na
ly
si
s 
be
ca
us
e 
of
 m
is
si
ng
 d
at
a.
Pa
tie
nt
s 
w
ith
 m
aj
or
 th
er
m
al
 
in
ju
ry
 a
re
 a
ss
oc
ia
te
d 
w
ith
 
co
ag
ul
op
at
hy
 a
nd
 th
is
 is
 a
n 
in
de
pe
nd
en
t p
re
di
ct
or
 o
f 
28
-d
ay
 m
or
ta
lit
y.
3b
Ta
bl
e 
1.
 (C
on
tin
ue
d)
 (C
on
tin
ue
d)
8 Scars, Burns & Healing
A
ut
ho
r, 
da
te
St
ud
y 
ty
pe
O
ut
co
m
e
Pa
ti
en
ts
 (n
)/
 d
et
ai
ls
Re
su
lt
s
Co
m
m
en
ts
Co
nc
lu
si
on
Le
ve
l o
f 
ev
id
en
ce
Va
n 
H
ar
en
 
et
 a
l.,
 2
01
32
5
Si
ng
le
-c
en
tr
e,
 
pr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
dy
M
ea
su
rin
g 
TE
G
, P
C,
 P
S,
 P
T,
 
A
PT
T 
an
d 
A
T 
III
 o
n 
bu
rn
 
pa
tie
nt
s 
on
 a
dm
is
si
on
 a
nd
 
in
ve
st
ig
at
e 
ch
an
ge
s 
of
 th
es
e 
pa
ra
m
et
er
s 
du
rin
g 
re
co
ve
ry
.
n 
=
 2
4 
(8
8%
 m
al
e)
n 
=
 2
1 
ha
d 
th
er
m
al
 
in
ju
rie
s,
 n
 =
 3
 h
ad
 
el
ec
tr
ic
al
 in
ju
rie
s.
M
ed
ia
n 
TB
SA
 b
ur
n 
w
as
 
29
%
, m
ed
ia
n 
ag
e 
49
 
ye
ar
s.
Re
pe
at
 T
EG
 a
t 1
 w
ee
k 
fo
r 1
6 
pa
tie
nt
s 
af
te
r a
dm
is
si
on
 w
as
 
hy
pe
rc
oa
gu
la
bl
e 
(P
 <
 0
.0
5)
Sm
al
l s
am
pl
e 
si
ze
. P
at
ie
nt
s 
di
sc
ha
rg
ed
 b
ef
or
e 
1 
w
ee
k 
w
er
e 
no
t 
fo
llo
w
ed
 u
p 
w
ith
 a
 s
ec
on
d 
sa
m
pl
e 
of
 b
lo
od
 te
st
s.
O
n 
ad
m
is
si
on
, c
oa
gu
la
tio
n 
pa
ra
m
et
er
s 
ar
e 
ge
ne
ra
lly
 n
or
m
al
 b
ut
 a
 
hy
pe
rc
oa
gu
la
bl
e 
st
at
e 
fo
llo
w
s 
du
rin
g 
re
co
ve
ry
. 
H
yp
er
co
ag
ul
ab
le
 p
at
ie
nt
s 
on
 a
dm
is
si
on
 m
ig
ht
 b
e 
at
 
hi
gh
er
 ri
sk
 o
f V
TE
.
2b
Lu
 e
t a
l.,
 
20
13
27
Si
ng
le
-c
en
tr
e,
 
re
tr
os
pe
ct
iv
e 
co
ho
rt
 s
tu
dy
D
et
er
m
in
in
g 
th
e 
in
ci
de
nc
e 
of
 A
TC
 in
 b
ur
ns
 p
at
ie
nt
s 
as
 
m
ea
su
re
d 
on
 a
dm
is
si
on
 P
T,
 
A
PT
T,
 p
la
te
le
ts
 a
nd
 H
b.
n 
=
 1
02
 (6
9.
6%
 m
al
e)
n 
=
 8
9 
w
ith
 1
5–
65
%
 
TB
SA
n 
=
 1
3 
w
ith
 6
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three level 3b (3550 patients)29–31 and two level 
1b (61 patients)2,32 evidence studies. The RCTs 
were conducted in Greece2 and Austria,32 the 
cohort studies were conducted in Greece,3 
USA,14,26,28,30 UK/Spain,29 Australia31 and Aus-
tria,27 the literature reviews were conducted in 
The Netherlands23 and USA24 and the case series 
was conducted in the USA.25 Although there is a 
wide geographical variance, the coagulation 
markers used appear to be similar across all units.
All studies matched the participants to the 
criteria being evaluated. Only the two RCTs2,32 
had equal representation of participant charac-
teristics, including age, sex and severity of burns 
injury. The remaining eight cohort studies3,14,26–31 
and one case series25 had a higher ratio of male 
participants, which can reduce the generalisabil-
ity of the evidence. All studies involved the adult 
population, except Barret et  al.,29 who also 
included children. Van Haren et  al.28 included 
three patients with electrical burn injuries as part 
of their study population in addition to their 21 
patients with thermal injuries. Park et al.14,26 used 
the same group of participants across two cohort 
studies; however, different outcomes, haemo-
static status using coagulation tests14 and coagula-
tion and inflammatory factors,26 were measured; 
therefore, both studies were included. The litera-
ture reviews included 5324 and 9223 journal arti-
cles, respectively, with publication dates of 
1968–2015. All studies reported explicit eligibil-
ity criteria and outcomes, which would minimise 
confounding variables and increase applicability. 
However, the case series reported that patients 
had co-existing morbidities including hyperten-
sion and HIV; therefore, this may have con-
founded the results.25
The severity of burn injury included in the 
studies varied between 3%25 and 66–100%30 
TBSA. All studies consistently reported that the 
level of coagulopathy was proportional to the 
percentage of TBSA burned, although no studies 
specifically looked at the degree of coagulopathy 
in relation to burn size, which would be more 
useful. Park et al.14,26 failed to report the extent 
of burn injuries, therefore affecting the applica-
bility of results.
Outcomes. All studies posed a clear research ques-
tion and identified relevant outcomes. These 
included testing useful markers for the coagula-
tion status of patients and determining the effect 
of these markers and their role in DIC. In addi-
tion, the haemostatic status of patients using rou-
tine laboratory tests and newer viscoelastic 
techniques were explored. Van Haren et  al.28 
concomitantly measured both TEG and standard 
PT and PTT in their study population. There 
were no studies comparing ROTEM against stan-
dard PT and APTT tests. Furthermore, cost com-
parisons did not appear to be considered in any 
of the studies.
Randomisation and blinding. One RCT involved a 
treatment group, receiving antithrombin, and a 
non-treated control group.2 The other RCT 
involved randomisation into either a case group 
whereby blood product use was based on a treat-
ment algorithm using ROTEM, or into a control 
group with blood products being given at the dis-
cretion of the clinician.32 Neither study described 
the process of randomisation, increasing the pos-
sibility of selection bias and neither study was 
blinded which may lead to observer bias and the 
possibility of a placebo effect.
Due to the nature of case series25 and cohort 
studies,3,14,26–31 especially in this small, specialised 
group of patients, randomisation was not possi-
ble. Therefore, participants may not accurately 
represent the population, which reduces its valid-
ity. Participants were largely self-selected during 
defined dates of admission to the intensive care 
unit. Although difficult to blind, the case/cohort 
studies employed standardised methods by hos-
pitals and clear outcomes were stated; therefore, 
bias was unlikely to have been introduced. It is 
appreciated that caution should be taken when 
interpreting results from case series; however, 
due to the limited literature, this case series25 
facilitated the publication of new observations 
and collectively can influence further, higher 
order research.
Limitations, statistical significance and quality of body 
of evidence. Power was not stated for any of the 
studies, and apart from Barret et al.,29 all studies 
were of small sample sizes; therefore, it is difficult 
to draw any definitive conclusions from their 
results. However, the clearly stated eligibility cri-
teria, demographics and clinical details across all 
studies add strength to their conclusions and 
recommendations.
The reported statistically significant results 
included: an increase in fibrinogen 48 h follow-
ing burn injury, P = 0.002;27 reduction in blood 
product requirements in burn patients managed 
using a ROTEM-based treatment algorithm for 
transfusion compared to clinicians discretion (P 
< 0.002);32 the improved ability to predict mor-
tality using coagulation (maximal amplitude on 
TEG) and inflammatory (TNF alpha levels) 
parameters (P < 0.001);26 elevated PT and APTT 
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in burn patients when compared to controls 
(both P < 0.05);14 repeat TEG samples show 
hypercoagulability in burn patients taken one 
week after admission which was more sensitive 
than PT and APTT measurements (P < 0.05);28 
biochemical coagulopathy on admission is an 
independent risk factor for 28-day mortality (P < 
0.05);31 the incidence of acute traumatic coagu-
lopathy in burn patients on admission is signifi-
cantly less than in trauma patients (P < 0.0001);30 
reduction in TPA (tissue plasminogen activator) 
and TAT (thrombin anti-thrombin) on day 1 
compared to day 4 in patients treated with 
antithrombin, compared to non-treated controls, 
and an increase in D-dimer on day 1 compared to 
day 4 of injury (both P < 0.05).2
The two literature reviews both highlighted 
the lack of high quality studies to base recom-
mendations on and recommended further inves-
tigations in the area of prophylactic venous 
thromboembolism (VTE) treatment and hyper-
coagulability in burn patients24 and coagulopa-
thy of severe burns and its management.23
A meta-analysis was not considered due to the 
variations in methodology and outcomes across 
all included studies which prevented direct com-
parison of coagulation measurements between 
studies to prove superiority of either.
Discussion
Coagulopathy after burn injury is influenced by a 
complex interplay of multiple factors and it is not 
always possible to predict the outcome as coagu-
lopathy can be disproportionate to the burn 
injury sustained.25,30,31 Current evidence suggests 
that burn injury involves an uncontrolled 
increase in the coagulation system, in proportion 
to the TBSA burned.8,33 Additionally, factors con-
tributing to a coagulopathic state include the 
depth of burns, inhalation injury and haemodilu-
tion in the resuscitative phase.8,31 In the early 
post-burn period, routine coagulation tests, PT 
and APTT, are not sensitive enough to detect the 
subtle changes in coagulation abnormalities, 
often only becoming abnormal once severe coag-
ulopathies are established.29 Several studies have 
found that in the majority of severe burns, PT 
and APTT are normal at presentation.8,30,33 
However, marked changes in specific coagula-
tion and fibrinolytic markers have been reported 
in the early post-burn period,3,11,12 and in one 
study, in the presence of normal PT and APTT.33 
The levels of coagulation-associated markers 
which signify a hypercoagulable state in the early 
post-burn period include increased fibrinogen, 
TAT complex, activated factor VII and decreased 
levels of the natural anticoagulants antithrombin 
III, protein C and protein S and the associated 
increases in markers of the fibrinolytic system 
include the fibrin degradation product D-dimer, 
TPA and TPA type 1.3,12,25,27,33 All studies reported 
a time course-related change in these markers, 
with results normalising between five and seven 
days unless complications developed. However, 
one study reported that repeat TEG measure-
ment one week after admission showed a transi-
tion to a hypercoagulable state despite VTE 
thromboprophylaxis.28
Management of severe bleeding caused by 
surgical debridement of wounds is known to be a 
clinical challenge and management can have a 
profound effect on patient outcome. It has been 
suggested that traditional plasma based coagula-
tion tests such as PT and APTT are of limited use 
in managing bleeding during surgical wound 
debridement of burn injury.14,25,27 Instead, whole 
blood tests such as TEG® or ROTEM® are supe-
rior and allow for targeted therapy of blood 
transfusions, which has been supported by a 
recent RCT in burn patients.32 Schaden et  al.32 
reported a significant reduction in allogenic 
blood product requirements during burn exci-
sion in patients managed with an algorithm 
based on trauma induced coagulopathy using 
POC ROTEM®, compared to those managed 
according to clinicians discretion. Most of the 
available literature describe TEG®/ROTEM®’s 
ability to monitor and guide blood product 
replacement, with very little literature on its abil-
ity to detect hypercoagulable states, such as those 
seen in burns. Park et al.14 reported TEG® to be 
more sensitive than plasma-based clotting assays 
(PT and APTT) in detecting hypercoagulable 
states in burned patients, and suggest TEG® as 
an additional method of assessing the efficacy of 
deep vein thrombosis prophylaxis in these high-
risk patients. Furthermore, Van Haren et  al.28 
detected a hypercoagulable state in all their 
patients one week after admission as measured 
by TEG sampling. Targeted therapy based on 
TEG®/ROTEM® results could improve patient 
outcome and allow for better allocation of health-
care resources; however, strong evidence is lack-
ing and further research is needed to support 
this before clinical guidelines can be developed 
and implemented.
Despite several studies investigating the 
effect of burns on coagulation, the exact time 
course of these haemostatic changes remains 
unknown as it is effected not only by the patho-
physiology of the burn, but also in response to 
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therapeutic interventions such as fluid resuscita-
tion, excisional surgery and transfusion. 
Hypothermia is a preventable problem in the 
early post-burn period, as a result of a combina-
tion of skin loss, hospital transfers often via air 
ambulance and impairment of thermoregula-
tion with anaesthesia. Mitra et al.8 demonstrated 
that hypothermia on presentation (35.5°C) was 
associated with early onset coagulopathy in a 
study of 163 patients with > 20% TBSA burns. 
Although hypothermia was not an in independ-
ent predictor of coagulopathy in this study, hypo-
thermia is well known to exacerbate coagulopathy 
and is a cause of morbidity during burn excision 
surgery.34 In a recent in vitro study of a new vis-
coelastic technique for clot microstructure, 
hypothermia was significantly associated with 
increased clotting times and the formation of 
weaker, more porous clots, prone to fibrinoly-
sis.35 Similar studies using this new technique 
have also demonstrated a significant effect of 
fluid haemodilution using both crystalloid and 
colloid fluids on coagulation in vitro. Clot 
strength and clot microstructure (fractal dimen-
sion) both decreased with progressive haemodi-
lution, which became significant at dilutions as 
low as 20%.36,37 Higher volumes of fluid adminis-
tration have been shown to be an independent 
predictor of early onset coagulopathy in burns 
(odds ratio [OR] 1.59; 95% confidence interval 
[CI] 1.02–9.3; P = 0.02), suggesting judicious 
fluid resuscitation regimes may help prevent 
coagulopathies in these patients.8
Although all studies describe an increase in 
coagulation markers in proportion to TBSA, no 
papers report on the specific changes seen at dif-
ferent severities of burn size, which would of 
course be of great interest to the burns physician. 
One study reported a TBSA threshold whereby 
burns over 6% TBSA result in a hypercoagulable 
state; however, this was a very small study of just 
five patients and therefore no firm conclusion 
can be taken from this.25 Both Kowal Vern et al.11 
and Garcia-Avello et al.12 demonstrated a signifi-
cant difference in coagulation markers between 
extensive (> 40% TBSA) and less extensive burns 
(< 40%TBSA) on day 1 post injury. The reason 
for this is most likely down to a number of fac-
tors, including a greater inflammatory reaction 
stimulating a more marked response by the coag-
ulation cascade. Also, larger volumes of fluid 
resuscitation with larger burns will lead to a dilu-
tional component to the alteration in coagula-
tion markers.11 On the other hand, Van Haren 
et al.28 reported no significant difference in TEG 
measurements between burn patients < 50% 
TBSA and burns > 50% TBSA in their study. 
Despite the fact that both surface area and depth 
of burn is proportional to the severity, none of 
the above studies specified the depth of burn 
injury. This is another relevant factor to consider 
as ‘the volume’ of a burn can be considered.
The clinical relevance of this burns-related 
coagulopathy remains unknown and needs 
assessing via large prospective studies to assess 
whether this indeed has any effect on outcome in 
terms of wound healing and overall prognosis. 
Early onset coagulopathy has been shown to be 
associated with higher volumes of blood product 
replacement, prolonged mechanical ventilation 
and extended ICU stays;26 however, no associa-
tion with wound healing or surgical complica-
tions have been reported in any previous studies. 
Early onset coagulopathy has been shown to be 
independently predictive with increased mortal-
ity in a study by Sherren et al.31 and the presence 
of overt DIC at presentation has been shown to 
be significantly related to organ failure and mor-
tality (P < 0.001; OR 10; 95% CI 3.23–32.26) in 
two studies by Lavrentieva et  al.2,3 The use of 
coagulation markers as a prognostic tool was sug-
gested by Park et al.26 who reported a scoring sys-
tem to predict the probability of mortality in 
traumatic and burn injuries. This is currently 
being used at an Army Medical Centre for 
research purposes, but there did not appear to 
be any follow-up results or recommendations. 
Strong evidence for the role of coagulation tests 
as markers for prognosis and outcome are still 
lacking and require further research.
Strengths of this review include consistent 
searches of available literature across five main 
databases, the transparent reporting of the 
search strategy, articles found, and inclusion and 
exclusion criteria. The entire body of evidence 
was evaluated and graded using the well-estab-
lished CASP framework22 and Oxford Centre for 
Evidence-Based Medicine,38 respectively.
Limitations of the study included the retrieval 
of only two RCTs requiring adaptation of our sys-
tematic review to include case series, reviews and 
cohort studies. The small body of evidence, sam-
ple sizes and disparate outcome measures which 
prevented direct comparisons proved to be a 
challenge in this study, which make it difficult to 
draw definitive conclusions.
Future work with regards to RCTs comparing 
burn and blood transfusion outcomes where 
management is based on TEG®/ROTEM® 
results vs. PT/APTT for comparison is advised to 
ascertain the usefulness of these POC tests in the 
burns setting.
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Conclusion
This study has identified limited level 1b evi-
dence that newer viscoelastic POC tests such as 
TEG and ROTEM appear to be sensitive at detect-
ing early coagulation abnormalities. These tests 
could prove to be beneficial in making immedi-
ate clinical decisions regarding treatment and 
prognosis in burn injuries and in predicting 
thromboembolic events; however, even when rec-
ognised there are no current guidelines for the 
management of burn-related coagulopathies. 
Further research in the form of a well-designed 
large multicentre RCT investigating the accuracy 
of routine laboratory and newer viscoelastic tests 
in diagnosing post-burn coagulation disorders is 
required before definitive recommendations can 
be produced.
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